Quest Diagnostics (DGX) Receivables (2009 - 2026)

Quest Diagnostics (DGX) has 18 years of Receivables data on file, last reported at $1.6 billion in Q1 2026.

• Quarterly Receivables rose 13.03% year-over-year to $1.6 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.6 billion (up 13.03% YoY) and the FY2025 annual result came in at $1.4 billion, up 7.98% from the prior year.
• Receivables advanced to $1.6 billion in Q1 2026 per DGX's latest filing, from $1.4 billion in the prior quarter.
• The five-year high for Receivables was $1.6 billion in Q1 2026, with the low at $1.2 billion in Q4 2022.
• Average Receivables over 5 years is $1.3 billion, with a median of $1.3 billion recorded in 2024.
• Year-over-year, Receivables fell 16.9% in 2022 and rose 13.03% in 2026.
• Quest Diagnostics' Receivables stood at $1.2 billion in 2022, then advanced by 1.26% to $1.2 billion in 2023, then gained by 7.77% to $1.3 billion in 2024, then grew by 7.98% to $1.4 billion in 2025, then increased by 12.71% to $1.6 billion in 2026.
• Business Quant data shows DGX's Receivables at $1.6 billion in Q1 2026, $1.4 billion in Q4 2025, and $1.5 billion in Q3 2025.